Cargando…

Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia

The major regulators of human acute lymphoblastic leukemia (ALL) cell growth and survival mediate their effects through the phosphoinositide 3-kinase (PI-3K)/mammalian target of rapamycin (mTOR) pathway. We have shown that the mTOR inhibitor everolimus extended survival in a non-obese diabetic/sever...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, Jacky, Welschinger, Robert, Hewson, John, Bradstock, Kenneth F., Bendall, Linda J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279386/ https://www.ncbi.nlm.nih.gov/pubmed/25361005

Ejemplares similares

mTOR Inhibition by Everolimus in Childhood Acute Lymphoblastic Leukemia Induces Caspase-Independent Cell Death
por: Baraz, Rana, et al.
Publicado: (2014)

Silencer of Death Domains Controls Cell Death through Tumour Necrosis Factor-Receptor 1 and Caspase-10 in Acute Lymphoblastic Leukemia
por: Cisterne, Adam, et al.
Publicado: (2014)

Disparate In Vivo Efficacy of FTY720 in Xenograft Models of Philadelphia Positive and Negative B-lineage Acute Lymphoblastic Leukemia
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2012)

Correction: Disparate In Vivo Efficacy of FTY720 in Xenograft Models of Philadelphia Positive and Negative B-lineage Acute Lymphoblastic Leukemia
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2012)

Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia
por: Badura, Susanne, et al.
Publicado: (2013)

Targeting mTOR in Acute Lymphoblastic Leukemia
por: Simioni, Carolina, et al.
Publicado: (2019)

Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice
por: Xie, Vicki, et al.
Publicado: (2018)

The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
por: Shi, Fei, et al.
Publicado: (2017)

Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment
por: Wu, Xianbo, et al.
Publicado: (2022)

Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
por: Shi, Fei, et al.
Publicado: (2018)

Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
por: Fransecky, Lars, et al.
Publicado: (2015)

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels
por: Bressanin, Daniela, et al.
Publicado: (2012)

Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway
por: Lonetti, Annalisa, et al.
Publicado: (2016)

Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
por: Tarantelli, Chiara, et al.
Publicado: (2020)

Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
por: Liu, Yang, et al.
Publicado: (2018)

Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update
por: Evangelisti, Camilla, et al.
Publicado: (2018)

Structural insights of a PI3K/mTOR dual inhibitor with the morpholino-triazine scaffold
por: Takeda, Takako, et al.
Publicado: (2016)

A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer
por: Luo, Leixuan, et al.
Publicado: (2023)

VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo
por: Shao, Zheren, et al.
Publicado: (2015)

Regulation of the bone marrow microenvironment by G-CSF: Effects of G-CSF on acute lymphoblastic leukaemia
por: Basnett, Jordan, et al.
Publicado: (2017)

Healthy CD4(+) T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia
por: Alameen, Ayman A.M., et al.
Publicado: (2016)

Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
por: Shoji, Keiko, et al.
Publicado: (2012)

Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway
por: Chen, Dongshao, et al.
Publicado: (2018)

Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors
por: Echeverry, N, et al.
Publicado: (2015)

Developing a novel dual PI3K–mTOR inhibitor from the prodrug of a metabolite
por: Zhou, Yan, et al.
Publicado: (2017)

Design, Synthesis and Biological Evaluation of Novel Phenylsulfonylurea Derivatives as PI3K/mTOR Dual Inhibitors
por: Zhao, Bingbing, et al.
Publicado: (2018)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

20(S)-Ginsenoside Rh2 displays efficacy against T-cell acute lymphoblastic leukemia through the PI3K/Akt/mTOR signal pathway
por: Xia, Ting, et al.
Publicado: (2020)

How do mTOR inhibitors fit in the landscape of treatment for relapsed acute lymphoblastic leukemia?
por: Pinchinat, Ashley, et al.
Publicado: (2022)

Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia
por: Simioni, Carolina, et al.
Publicado: (2016)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Targeting PI3K/mTOR Signaling in Cancer
por: Arcaro, Alexandre
Publicado: (2014)

Therapeutic targets for cancer: Current concepts with PI 3-K, Akt, & mTOR
por: Maiese, Kenneth
Publicado: (2013)

Novel 4-Acrylamido-Quinoline Derivatives as Potent PI3K/mTOR Dual Inhibitors: The Design, Synthesis, and in vitro and in vivo Biological Evaluation
por: Ma, Xiaodong, et al.
Publicado: (2019)

Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo
por: Jonchere, Barbara, et al.
Publicado: (2023)

SPR965, a Dual PI3K/mTOR Inhibitor, as a Targeted Therapy in Ovarian Cancer
por: Tran, Arthur-Quan, et al.
Publicado: (2021)

Evaluation of a Dual PI3K/mTOR Inhibitor PF-04691502 against Bladder Cancer Cells
por: Shang, Xiaosong, et al.
Publicado: (2022)

Design, Synthesis, and Biological Evaluation of Sulfonamide Methoxypyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors
por: Gao, Haotian, et al.
Publicado: (2023)

Identification of phytochemical as a dual inhibitor of PI3K and mTOR: a structure-based computational approach
por: Kumar, B. Harish, et al.
Publicado: (2022)

Dual PI3K/mTOR inhibitor NVP-BEZ235 decreases the proliferation of doxorubicin-resistant K562 cells
por: Li, Jie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hs5gc7e25cvn85hehsvh2nnqdd